Polarean Imaging PLC Completion of patient enrolment & PDMR appointment

Fecha : 07/11/2019 @ 01:00
Fuente : UK Regulatory (RNS & others)
Emisora : Polarean Imaging Plc (POLX)
Cotización : 20.0  0.0 (0.00%) @ 02:00
Polarean Imaging Cotización de acciones Gráfica

Polarean Imaging PLC Completion of patient enrolment & PDMR appointment

Polarean Imaging (LSE:POLX)
Gráfica de Acción Histórica

2 meses : De Oct 2019 a Dic 2019

Haga Click aquí para más Gráficas Polarean Imaging.

TIDMPOLX

RNS Number : 5570S

Polarean Imaging PLC

07 November 2019

7 November 2019

Polarean Imaging Plc

("Polarean" or the "Company")

Completion of patient enrolment for Clinical Trials and PDMR Appointment

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary magnetic resonance imaging (MRI) drug-device combination, announces that the enrolment for its Phase III non-inferiority clinical trials (the "Clinical Trials") is now complete for both the lung transplant pathway and the lung resection pathway. The Clinical Trials enrolled a total of 80 patients of which 48 were in the lung transplant and 32 were in lung resection, respectively.

The aim of the Clinical Trials is to demonstrate non-inferiority of the Company's drug-device combination, which uses hyperpolarised 129-Xenon gas MRI, against an approved comparator for the diagnostic evaluation of pulmonary ventilation.

The readout process will now move to image and statistical analysis. This process is currently expected to take approximately 10 weeks and will conclude with the readout of the Clinical Trials.

On the current advice of Polarean's regulatory consultants, the completion of readout will form the basis for a Pre-New Drug Application ("NDA") Meeting with the FDA. Following the Pre-NDA Meeting and incorporation of its conclusions into the NDA submission, the process will conclude with the Company's NDA submission, currently estimated by the end of Q2 2020.

PDMR Appointment

Consistent with Polarean's target of achieving commercial sales upon receiving FDA approval, the Company also announces that Mr. Alex Dusek has joined as Vice-President of Commercialisation (non-Board role) with immediate effect. Prior to joining Polarean, Mr. Dusek has led multiple biopharmaceutical product launches in pulmonary disease, oncology cell therapy and HIV therapeutics, including at Bayer and United Therapeutics. Mr. Dusek earned a B.A. in Linguistics from the College of William and Mary, pre-medical programme at Columbia University, and received his M.B.A. from the University of North Carolina, Kenan-Flagler Business School.

Richard Hullihen, CEO of Polarean, said: "The Company is pleased to have successfully completed enrolment for its Clinical Trials and looks forward to the next stage of statistical analysis ahead of readout and the proposed submission of the NDA. We are also pleased to welcome Alex Dusek to our team, as he brings a wealth of direct pharmaceutical industry launch preparation and commercialisation experience to Polarean, as we ramp up our commercialisation planning."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries:

 
 Polarean Imaging plc                             www.polarean.com / www.polarean-ir.com 
 Richard Hullihen, Chief Executive Officer                               Via Walbrook PR 
 Richard Morgan, Chairman 
 
 SP Angel Corporate Finance LLP                                 Tel: +44 (0)20 3470 0470 
 David Hignell, Soltan Tagiev (Corporate 
  Finance) 
  Vadim Alexandre / Rob Rees (Corporate Broking) 
 
 Walbrook PR                         Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com 
 Paul McManus / Anna Dunphy                       Mob: +44 (0)7980 541 893 / +44 (0)7879 
                                                                                 741 001 
 
 

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution medical imaging market.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas ((129) Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel diagnostic approach, offering a non-invasive and radiation-free functional imaging platform which is more accurate and less harmful to the patient than current methods. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.

The Group also develops and manufactures high performance MRI radiofrequency (RF) coils which are a required component for imaging (129) Xe in the MRI system. The development of these coils by the Group facilitates the adoption of the Xenon technology by providing application-specific RF coils which optimise the imaging of (129) Xe in MRI equipment for use as a medical diagnostic as well as a method of monitoring the efficacy of therapeutic intervention.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCBFBLTMBJMBBL

(END) Dow Jones Newswires

November 07, 2019 02:00 ET (07:00 GMT)

Su Consulta Reciente
BMV
FIBRAPL14
Fibra Prol..
BMV
AMXL
América Mó..
BMV
ME
IPC México
BMV
ALSEA*
Alsea
FX
USDMXN
United Sta..
Las acciones que ha visto aparecerán en este recuadro, lo que le permite volver fácilmente a las cotizaciones que ha consultado previamente
Registrarse ahora para crear su lista personalizada de acciones en streaming.

Cotizaciones PLUS están en tiempo real. Cotizaciones NYSE y AMEX están con retraso de por lo menos 20 minutos.
El resto de las cotizaciones están con retraso de por lo menos 15 minutos al menos que se indique lo contrario.

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

P: V:mx D:20191207 18:56:43